Established AOD-9604 stacks
Fat Loss Research Protocol
Goal: Complementary lipolytic and appetite-suppressing signals
Researchers have theorized combining AOD-9604's direct lipolytic action with GLP-1-mediated appetite reduction. This is a research model, not a clinical recommendation.
Body Recomposition
Goal: Targeted fat metabolism with GH-axis support
Some research protocols pair AOD-9604 for fat-specific signaling with a GHRH analogue to study the combined metabolic and body-composition effects.
How to think about stacking
- Mechanism diversity beats redundancy. Pairing compounds that hit different pathways usually outperforms stacking two compounds with similar mechanisms.
- Track one variable at a time. Starting two peptides simultaneously makes it impossible to attribute effects. Research protocols typically introduce stacks sequentially.
- Side-effect interactions. Some peptides compound each other's side effects (e.g., GLP-1 agonists with other GI-active compounds). Review side-effect profiles before stacking.